Dr. Rebecca Kristeleit specializes in the treatment of gynaecological cancers, including cervical, endometrial, and ovarian cancer. She has expertise in novel therapies and molecular testing for gynaecological cancer and has led or been involved in several successful new drug applications, including rucaparib, lurbinectedin, and dostarlimab. Dr. Kristeleit joined her current practice from UCL in early 2020 to lead the expansion of clinical and translational research in gynaecological cancer. She leads a large portfolio of Phase I-III clinical studies, including immunotherapy for gynaecological malignancies. Dr. Kristeleit qualified from the University of Manchester in 1995 and completed a BSc in medical science at the University of St Andrews. She received an ERASMUS Scholarship to study in Switzerland and completed an elective at Massachusetts General Hospital, Harvard University. She specialized in medical oncology at the Royal Marsden and obtained a CRUK-funded clinical research fellowship at the Institute of Cancer Research, being awarded a PhD in the clinical pharmacology of HDAC inhibitors. She completed a Senior Fellowship at the Royal Marsden's Drug Development Unit in 2009. Dr. Kristeleit is a member of the Target Ovarian Cancer Scientific Advisory Board, the Oncology and Haematology Expert Advisory Group for the Commission on Human Medicines, and the ESMO Faculty from 2021 to 2025. She has over 100 peer-reviewed publications and frequently speaks at national and international conferences, advising pharmaceutical companies on their gynaecological cancer drug development.